Key Points
- CEO William Sibold sold 5,221 Madrigal Pharmaceuticals shares at an average price of $542.39, generating approximately $2.83 million. The sale, conducted under a Rule 10b5-1 plan, covered tax withholding tied to vested equity awards and reduced his stake by 2.57%.
- Madrigal reported quarterly revenue of $364.25 million, up 71.2% year over year, and an adjusted loss of $1.99 per share that beat analysts’ estimate of a $2.68 loss.
- Wall Street remains broadly positive, with 15 Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $699.64 versus the stock’s reported $534.49 price.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CEO William Sibold sold 5,221 shares of the business's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the sale, the chief executive officer owned 197,746 shares of the company's stock, valued at approximately $107,255,452.94. The trade was a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
William John Sibold also recently made the following trade(s):
- On Wednesday, September 9th, William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $535.59, for a total transaction of $3,407,423.58.
Madrigal Pharmaceuticals Trading Up 0.3%
Madrigal Pharmaceuticals stock opened at $534.49 on Friday. The firm's 50-day moving average is $530.99 and its 200-day moving average is $507.63. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20. Madrigal Pharmaceuticals, Inc. has a 1 year low of $393.61 and a 1 year high of $615.00. The company has a market cap of $12.35 billion, a P/E ratio of -41.47 and a beta of -0.98.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, beating analysts' consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The business had revenue of $364.25 million during the quarter, compared to the consensus estimate of $352.13 million. During the same quarter in the prior year, the firm earned ($1.90) EPS. The company's revenue for the quarter was up 71.2% compared to the same quarter last year. On average, equities analysts expect that Madrigal Pharmaceuticals, Inc. will post -7.03 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on MDGL. Citigroup reaffirmed an "outperform" rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 17th. Piper Sandler restated an "overweight" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Barclays lowered their price objective on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an "overweight" rating for the company in a research note on Monday, August 3rd. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Fifteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $699.64.
View Our Latest Stock Report on Madrigal Pharmaceuticals
Institutional Investors Weigh In On Madrigal Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in MDGL. California State Teachers Retirement System grew its holdings in Madrigal Pharmaceuticals by 54,067.5% during the second quarter. California State Teachers Retirement System now owns 9,233,929 shares of the biopharmaceutical company's stock worth $4,958,158,000 after acquiring an additional 9,216,882 shares during the period. Jupiter Topco LLC acquired a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at about $1,039,650,000. Paulson & CO. Inc. acquired a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at about $719,524,000. BlackRock Inc. bought a new position in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at about $644,753,000. Finally, Janus Henderson Group PLC boosted its position in shares of Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company's stock valued at $1,051,727,000 after purchasing an additional 433,804 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic diseases, particularly nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).
The company's lead product is Rezdiffra (resmetirom), an oral, thyroid hormone receptor beta agonist designed to target underlying liver disease. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
